Figure 6.

Examination of Pathology and Serum after 2-Week Systemic Delivery of Z Polymer-Formulated PMO or Z-PMO Conjugate in mdx Mice Aged 4–5 Weeks

PMO (1 mg) only was used as controls. All other samples were from muscles treated with polymer-conjugated or simple formulated PMO (0.5 or 1 mg) in 100 μL saline. (A) H&E staining of liver and kidney tissue from the normal C57BL/6 mice, untreated mdx mice, PMO-, Z/PMO-, and Z-PMO-treated mdx mice (1 mg PMO, 1 mg Z7/1 mg PMO, 1 mg Z8-PMO; original magnification, ×200; scale bar, 200 μm). (B) The levels of serum enzymes, creatine kinase (KU/L), creatinine (mg/L), urea nitrogen (mg/mL), total bilirubin (mg/L), calcium (mg/dL), alanine transaminase (ALT) (U/dL), alkaline phosphatase (ALP) (U/dL), and ɤ-glutamyltransferase (GGT) (U/L). n = 5; *p ≤ 0.05 compared with untreated mdx mice. Two-tailed Student’s t test.